Posted by Michael Wonder on 16 Mar 2017
Cardiome receives Notice of Compliance from Health Canada for its Brinavess NDS
14 March 2017 - Cardiome Pharma Corporation announced today that it received a Notice of Compliance for Brinavess (vernakalant hydrochloride, IV) from Health Canada, which enables Cardiome to begin commercialising Brinavess in Canada.
Brinavess is indicated for the rapid conversion of recent onset atrial fibrillation (“AF”) to sinus rhythm for: non-surgery patients with AF ≤ 7 days; and post-cardiac surgery patients with duration of AF ≤ 3 days.
Brinavess is not recommended for conversion of atrial flutter to sinus rhythm.
